Toronto, Canada (PRWEB) June 21, 2013
Last year’s renewal of the Prescription Drug User Fee Act indicates that the FDA will require all submissions to include the clinical data in a standard format, within approximately 3 years. This standard is assumed to be the Study Data Tabulation Model (SDTM) maintained by CDISC.
Join us for an exciting webinar, led by experts from OmniComm and Alkermes, on strategies for incorporating SDTM in all your studies.
This webinar will:
Cover mapping SDTM specifications during study design and also will describe the benefits of having an SDTM database available during study conduct and having the final datasets within 24 hours of database lock
- Provide a brief overview of the technology that provides these capabilities
To learn more about the event, visit: http://xtalks.com/SDTM-in-Real-Time.ashx.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx.
Karen Lim (416) 977-6555 ext 227
Read the full story at http://www.prweb.com/releases/2013/6/prweb10852093.htm.
Page: 1 Related biology technology :1
Copyright©2012 Vocus, Inc.
All rights reserved
. Positive Clinical Study Results for BSPs HyperQ Technology2
. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting3
. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study4
. Marshall study shows nanoparticles used as additives in diesel fuels can travel from lungs to liver5
. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss6
. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV21979447
. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation8
. Singapore scientists lead human embryonic stem cell study9
. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly10
. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain11
. Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat